Study on the Correlation of Gene Polymorphism with Antiplatelet Efficacy of Clopidogrel in PAD Patients
10.6039/j.issn.1001-0408.2017.26.02
- VernacularTitle:PAD患者基因多态性与氯吡格雷抗血小板疗效的相关性研究
- Author:
Xiaoyu XU
;
Yang LIN
;
Xiujin SHI
;
Xiqiao XU
- Keywords:
Peripheral artery disease;
Clopidogrel;
Gene polymorphism;
CYP2C19 gene;
ABCB1 gene;
PON1 gene;
P2Y12 gene;
Antiplatelet efficacy
- From:
China Pharmacy
2017;28(26):3604-3609
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the correlation of gene polymorphism in peripheral artery disease(PAD)patients with antiplatelet efficacy of clopidogrel. METHODS:Reviewing related domestic and foreign literatures in recent years,the correlation of gene polymorphism in PAD patients with antiplatelet efficacy of clopidogrel was summarized and analyzed. RESULTS&CON-CLUSIONS:At present,a variety of genes associated with clopidogrel antiplatelet efficacy and major adverse cardiovascular events (MACE)have been identified,including cytochrome P450(CYP)2C19,adenosine three phosphate binding cassette B subfamily 1 (ABCB1),paraoxonase 1 (PON1) and adenosine diphosphate P2Y12 receptor (P2Y12),etc. CYP2C19*2,*3 allele may reduce the antiplatelet effect of clopidogrel. Their correlation has been confirmed by a number of studies,and study results are broadly con-sistent. Mutations in the ABCB1 C3435T and PON1 Q192R sites may lead to a lower response to clopidogrel and increase the risk of MACE;but there is a lack of large-scale prospective clinical studies,and the present results are inconsistent. P2Y12 gene poly-morphism in PAD patients has not been found to be significantly associated with clopidogrel efficacy.
